Plain-English translation of NCT06540833 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This study is testing a new medication called to see if it can help reduce psychotic symptoms—such as hallucinations and false beliefs—in people with Alzheimer's disease. Psychosis can be a distressing part of Alzheimer's, and this research aims to find a safer, more effective treatment option for these symptoms.
Psychotic symptoms in Alzheimer's disease are common and difficult to manage, and current treatments may not work well or can cause serious side effects. This trial is exploring whether this medication could offer a better way to help patients and their families.
You likely qualify if…
You likely don't qualify if…
The study lasts about 12 weeks total. First, you'll have a screening visit (up to 4 weeks) to confirm you're eligible. Then you'll be randomly assigned to receive either the new medication or a placebo for 6 weeks, during which you'll take the study treatment at home and attend study visits. Finally, you'll return for a follow-up safety visit about 30 days after your last dose. Your caregiver will be involved throughout to help monitor your progress and safety.
AI-generated summary from trial data · Jul 13, 2026 · Not medical advice
United States